Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;22(1):197-199.e3.
doi: 10.1016/j.cgh.2023.05.019. Epub 2023 May 26.

NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Jia Hong Koh  1 , Cheng Han Ng  2 , Benjamin Nah  1 , Darren Jun Hao Tan  3 , Rohit Loomba  4 , Daniel Q Huang  5 ; Nash HCC Transplant Collaborative
Collaborators, Affiliations

NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Jia Hong Koh et al. Clin Gastroenterol Hepatol. 2024 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

These authors disclose the following: Cheng Han Ng serves as a consultant to Boxer Capital. Rohit Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, Astra-Zeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc, Madrigal, Metacrine, Inc, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 Bio, Terns Pharmaceuticals, and Viking Therapeutics; his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes, and Terns Pharmaceuticals; and he is cofounder of LipoNexus Inc. Daniel Q. Huang has served as an advisory board member for Eisai. Mazen Noureddin serves as a consultant to Boxer Capital. The remaining authors disclose no conflicts.

Figures

Figure 1.
Figure 1.
(A) Waitlisted candidates with hepatocellular carcinoma. (B) Liver transplant recipients with hepatocellular carcinoma.
See this image and copyright information in PMC

References

    1. Huang DQ, et al. Cell Metab 2022;34:969–977. - PMC - PubMed
    1. Tan DJH, et al. Lancet Oncol 2022;23:521–530. - PubMed
    1. Younossi Z, et al. Clin Gastroenterol Hepatol 2019;17:748–755. - PubMed
    1. Wong RJ, et al. JAMA Netw Open 2020;3:e1920294. - PubMed
    1. Austin PC, et al. Circulation 2016;133:601–609. - PMC - PubMed

Publication types

MeSH terms